What are the annual cases of Non-Hodgkin's Lymphoma (NHL) worldwide?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Annual Cases of Non-Hodgkin's Lymphoma Worldwide

In 2020, approximately 544,000-545,000 new cases of Non-Hodgkin's Lymphoma (NHL) were diagnosed globally, with around 260,000 deaths from the disease. 1, 2

Global Incidence Data

The most recent comprehensive global data provides the following epidemiological picture:

  • New cases annually: 544,000-545,000 worldwide in 2020 1, 2
  • Deaths annually: Approximately 260,000 globally in 2020 1, 2
  • United States: 69,740 new cases estimated in 2013, with 19,020 deaths 3
  • United States (earlier data): 55,000-60,000 new cases annually, representing approximately 4% of all new cancer cases 3, 4

Regional Distribution Patterns

The geographic burden of NHL shows marked variation:

  • Eastern Asia: Accounts for 24.9% of all global cases 1
  • Northern America: Represents 15.1% of cases 1
  • South-Central Asia: Comprises 9.7% of cases 1
  • European Union crude incidence: 3-4 per 100,000 population per year for large cell lymphoma (which constitutes 30-58% of NHL) 3

Projected Future Burden

By 2040, NHL incident cases are projected to rise to approximately 778,000 globally, representing a significant increase driven primarily by aging populations and demographic changes. 2

Important Epidemiological Context

The incidence of NHL has demonstrated concerning trends:

  • Historical increase: NHL incidence increased approximately 168% since 1975 in the United States 5
  • Recent trends: A worldwide increase of approximately 30% occurred in the 5 years prior to 2010 6
  • Current pattern: Incidence rates have stabilized in the past decade after dramatic increases starting around 1970, though absolute case numbers continue rising due to population aging 7, 2

High-Risk Geographic Regions

Incidence rates are highest (>10 per 100,000 for both sexes combined) in:

  • Australia and New Zealand 1
  • Northern America 1
  • Northern Europe 1
  • Western Europe 1

However, mortality rates are disproportionately higher (>3 per 100,000) in low- and middle-income regions including Africa, Western Asia, and Oceania, reflecting disparities in access to diagnostic and treatment facilities. 1

References

Research

Global patterns of non-Hodgkin lymphoma in 2020.

International journal of cancer, 2022

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Non-Hodgkin lymphoma: diagnosis and treatment.

Mayo Clinic proceedings, 2005

Research

Epidemiology of Non-Hodgkin's Lymphoma.

Medical sciences (Basel, Switzerland), 2021

Guideline

Epidemiology of Lymphoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Epidemiology of non-Hodgkin lymphoma.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.